Page 3 - Scientific Library
Immunotherapy Screening - A focus on PD-1/PD-L1/PD-L2 Pathway in drug discovery
The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory
Immunotherapy - BLTA:HVEM, CD47:SIRPα in drug discovery
The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory
Where can I find the best PARPs?
Poly (ADP-ribose) polymerase (PARP) is a family of proteins which catalyze the NAD-dependent addition of Poly ADP-ribose (PAR) chains to nuclear proteins. PARPs play key signaling roles in apoptosis,
Immunotherapy Screening - GITR:GITRL pathway
In previous blogs, I invited you to read about the relevance of the B7-1 : CD28, B7-1 : CTLA4, the BLTA:HVEM, CD47:SIRPα , and the PD-1/PD-L1/PD-L2 pathway for immunotherapy screenings and discussed
Immunotherapy Screening - CD40:CD40L pathway
In my previous blogs, I invited you to read about the relevance of the B7-1 : CD28, B7-1 : CTLA4, the BLTA:HVEM, CD47:SIRPα , the GITR:GITRL and the PD-1/PD-L1/PD-L2 pathway for immunotherapy screenings
Immunotherapy Screening - CD137:CD137L pathway
In previous blogs, I invited you to read about the relevance of the B7-1 : CD28, B7-1 : CTLA4, the BLTA:HVEM, CD47:SIRPα , the GITR:GITRL, the CD40:CD40L and the PD-1/PD-L1/PD-L2 pathway for immunotherapy
Immunotherapy Screening - IDO pathway
In previous blogs, I invited you to join me in exploring the relevance of the following pathways:
- B7-1 : CD28, B7-1 : CTLA4
- BLTA:HVEM, CD47:SIRPα
- GITR:GITRL
- CD40:CD40L
- PD-1/PD-L1/PD-L2
- CD137:CD137L
Â
Caspases as pharmaceutical targets - screening for inhibitors?
Caspases (cysteine-dependent aspartate-directed proteases) belong to the family of cysteine proteases and are involved in networks controlling cell death (apoptosis and necrosis) and inflammation.
Modulating or inhibiting Caspase activities
In a previous post, I discussed Caspases as pharmaceutical targets - how to screen for inhibitors?
Today I would like to concentrate on Caspase inhibitors/modulators, which allow for in-depth characterisation
